PanGenex (PGXC) Provides Product Update on LIPIDEME(TM)

In June, 2008, PanGenex Corporation (Pink Sheets:PGXC) formally introduced LIPIDEME(TM), the all-natural product formulated to address cardiovascular health by having a positive impact on blood lipids. LIPIDEME, made from scientifically proven ingredients is the first product to combine the triglyceride-lowering power of Omega-3 fatty acids with the cholesterol managing ability of phytosterols and tocotrienols – plus the free-radical fighting capacity of Coenzyme Q10 (CoQ10).

Since the introduction of LIPIDEME, PanGenex’s customers have experienced significant reductions in blood lipid levels. Dr. Gregory Zwirn, a Chiropractic Physician, and owner of Axis Chiropractic in Tampa, FL states, “I struggled with high cholesterol for years. After taking LIPIDEME for about 2 months, my total cholesterol dropped nearly 60 points.” Dr. Zwirn, currently the president of the Hillsborough Chiropractic Society and a member of the Florida Chiropractic Association, went on to say that his patients were experiencing similar, positive results.

“LIPIDEME is a safe and effective way to naturally manage your blood lipids. It’s the best product I have come across … it is cost effective, easy to take, and it obviously works to help promote cardiovascular health. LIPIDEME is the gold standard in natural cholesterol lowering supplements.”

Mrs. Sandra Kreul, MSN, ARNP, CLS and one of only a few registered Lipidologists in the country, has begun a 60-day marketing trial this month in order to further quantify the heart healthy effects of LIPIDEME on known cardiovascular risk factors such as cholesterol, triglycerides, homocysteine, and blood pressure. Volunteers are recruited directly from her practice which she shares with cardiologist, Dr. Benedict Maniscalco.

“We are anxious to spread the word of the efficacy of LIPIDEME through our growing network of health care practitioners,” stated Jeff Roman, CEO and President of PanGenex. “LIPIDEME is making a difference in the lives of our customers and practitioner resellers and we look forward to reaching people with heart healthy solutions.”

LIPIDEME is formulated with pharmaceutical grade fish oil that is over 86% pure Omega-3s, the highest concentration available without a prescription for heart, mental, joint and skin health. The Omega-3s in LIPIDEME are triple molecularly distilled and rigorously tested to ensure that there are no detectable levels of Mercury, PCBs, or other toxins or heavy metals. The US Food and Drug Administration and the American Heart Association all recognize that the consumption of Omega-3 fatty acids from fish provide much needed protection for your heart.

About PanGenex Corporation:

PanGenex is a publicly traded corporation (PINK SHEETS:PGXC) and pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as, and


Cautionary Statement about Forward-Looking Statements

This press release contains “forward-looking statements,” which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as “expects,””anticipates,””intends,””plans,””believes,””seeks” or “will.” Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Leave a Reply

Your email address will not be published. Required fields are marked *